Skip to main content
Tirzepatide Research

Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics

BMJ Open Diabetes Research & Care·March 30, 2026

John P. H. Wilding, et al.

Summary

Safety and efficacy analysis of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics.

Study Details
Study Design

Analysis across baseline characteristics

Indication

Type 2 diabetes

Intervention

Switch from dulaglutide to tirzepatide

Species

Human

External Links
Metrics
Citations
0
Evidence QualityN/A
Related PeptideTirzepatide13 papers